Healthcare sales up 7% at Novo Nordisk:
This article was originally published in Clinica
First-half revenues at Novo Nordisk's healthcare business rose 7% to DKr 5,210 ($888 million) compared with 1995. The Danish healthcare and enzyme company reported strong sales growth of its Penfill for NovoPen and the disposable NovoLet diabetes delivery systems, especially in Japan. US sales rose around 10%. Group turnover was up 2% in the first six months to DKr 7,051 million compared with the corresponding period in 1995. Net income was DKr 873 million, up 16%.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.